Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
Invesco China Technology ETF
CQQQ
$3.19B
| $1.38M | ﹤0.01% |
26,500
-3,100
| -10% | -$169K |
|
3177
Merchants Bancorp
MBIN
$2.54B
| $1.38M | ﹤0.01% |
40,404
+3,879
| +11% | +$127K |
|
3178
Donegal Group Class A
DGICA
$696M
| $1.38M | ﹤0.01% |
68,872
+7,586
| +12% | +$149K |
|
3179
Dine Brands
DIN
$440M
| $1.37M | ﹤0.01% |
42,762
+7,313
| +21% | +$212K |
|
3180
Weis Markets
WMK
$1.77B
| $1.37M | ﹤0.01% |
21,401
-4,744
| -18% | -$317K |
|
3181
Groupon
GRPN
$894M
| $1.37M | ﹤0.01% |
77,776
-11,859
| -13% | -$223K |
|
3182
Red Cat Holdings
RCAT
$1.56B
| $1.37M | ﹤0.01% |
172,511
+50,301
| +41% | +$481K |
|
|
RHLD
3183
Resolute Holdings Management
RHLD
$1.08B
| $1.37M | ﹤0.01% |
6,624
+643
| +11% | +$95.1K |
|
3184
CALL
Zillow
Z
$8.08B
| $1.36M | ﹤0.01% |
20,000
| – | – |
|
3185
Sprinklr
CXM
$1.65B
| $1.36M | ﹤0.01% |
175,342
+14,193
| +9% | +$108K |
|
3186
CALL
Huntington Ingalls Industries
HII
$12.8B
| $1.36M | ﹤0.01% |
+4,000
| New | +$1.24M |
|
3187
Nu Skin
NUS
$236M
| $1.36M | ﹤0.01% |
141,236
+6,763
| +5% | +$70K |
|
3188
US Global Jets ETF
JETS
$832M
| $1.36M | ﹤0.01% |
48,331
-104,661
| -68% | -$2.72M |
|
3189
ThredUp
TDUP
$416M
| $1.36M | ﹤0.01% |
212,177
+76,859
| +57% | +$622K |
|
|
FBRT
3190
Franklin BSP Realty Trust
FBRT
$675M
| $1.36M | ﹤0.01% |
135,101
+12,504
| +10% | +$131K |
|
3191
CALL
Sweetgreen
SG
$721M
| $1.35M | ﹤0.01% |
200,300
| – | – |
|
3192
Icon
ICLR
$12.9B
| $1.35M | ﹤0.01% |
7,426
+5,456
| +277% | +$972K |
|
3193
UroGen Pharma
URGN
$2.34B
| $1.35M | ﹤0.01% |
57,744
+2,125
| +4% | +$46.1K |
|
3194
Varex Imaging
VREX
$780M
| $1.35M | ﹤0.01% |
116,063
+10,910
| +10% | +$128K |
|
|
AEBI
3195
Aebi Schmidt Holding AG
AEBI
$1.06B
| $1.35M | ﹤0.01% |
106,787
-25,392
| -19% | -$303K |
|
3196
National Beverage
FIZZ
$2.93B
| $1.35M | ﹤0.01% |
42,340
+7,079
| +20% | +$243K |
|
3197
Rush Enterprises Class B
RUSHB
$9.37B
| $1.35M | ﹤0.01% |
23,975
-110
| -0.5% | -$6.01K |
|
3198
Ezcorp Inc
EZPW
$1.76B
| $1.35M | ﹤0.01% |
69,441
-1,864
| -3% | -$35.1K |
|
3199
Zumiez
ZUMZ
$319M
| $1.35M | ﹤0.01% |
51,636
+1,763
| +4% | +$42.3K |
|
|
SEI
3200
PUT
Solaris Energy Infrastructure
SEI
$3.94B
| $1.34M | ﹤0.01% |
29,200
-70,800
| -71% | -$3.42M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.